About CNSDose
CNSDose is a company based in Melbourne (Australia) founded in 2015 was acquired by Incite Health in February 2023. CNSDose has raised $1.01 million across 2 funding rounds from investors including Pitchblak, Melbourne Accelerator Program and CNSDose. CNSDose operates in a competitive market with competitors including MedGenome, Foundation Medicine, Personalis, Veritas Genetics and Burning Rock, among others.
- Headquarter Melbourne, Australia
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$1.01 M (USD)
in 2 rounds
-
Latest Funding Round
$1 M (USD), Seed
Jul 13, 2016
-
Investors
Pitchblak
& 2 more
-
Employee Count
Not available
-
Acquired by
Incite Health
(Feb 15, 2023)
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Funding Insights of CNSDose
CNSDose has successfully raised a total of $1.01M across 2 strategic funding rounds. The most recent funding activity was a Seed round of $1 million completed in July 2016. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in CNSDose
CNSDose has secured backing from 3 investors, including venture fund investors. Prominent investors backing the company include Pitchblak, Melbourne Accelerator Program and CNSDose.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
-
|
Locked | Locked | Locked | |
|
Startup founders are supported through accelerator and pre-accelerator programs.
|
Locked | Locked | Locked | |
|
Genetic testing for personalized mental health medication is provided.
|
Locked | Locked | Locked |
Investor details for CNSDose
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by CNSDose
Investment portfolio details for CNSDose
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - CNSDose
Detailed financials for CNSDose
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Cnsdose Comparisons
Peer comparison for CNSDose
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of CNSDose
CNSDose operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as MedGenome, Foundation Medicine, Personalis, Veritas Genetics and Burning Rock, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
DNA sequencing, bioinformatics, and multiomics services are provided.
|
|
| Locked | Locked | Locked |
Genomics-based diagnostic tests for cancer are provided.
|
|
| Locked | Locked | Locked |
Genomic sequencing and diagnosis software is provided for healthcare.
|
|
| Locked | Locked | Locked |
Genetic testing products for health risks and traits are offered.
|
|
| Locked | Locked | Locked |
Personalized cancer diagnostics are developed using genomic big data analysis.
|
|
| Locked | Locked | Locked |
Drug and companion diagnostics for multi-drug resistant cancers are developed.
|
Detailed competitors of CNSDose
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Cnsdose
Complete news archive for CNSDose
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about CNSDose
CNSDose was founded in 2015 and raised its 1st funding round 1 year after it was founded.
CNSDose is headquartered in Melbourne, Australia. It is registered at Melbourne, Victoria, Australia.
CNSDose is a funded company, having raised a total of $1.01M across 2 funding rounds to date.
CNSDose was founded in 2015 in Melbourne, Australia, within the pharmacogenomics sector. Tools are provided to evaluate hepatic metabolism and efflux transporters via genomics, determining anti-depressant efficiency across the blood-brain barrier. Saliva samples from patients are processed at affiliated labs, with reports accessed by doctors through a secure cloud server for prescribing decisions. Operations focus on personalized treatment support in mental health care.
CNSDose's top competitors include Foundation Medicine, MedGenome and Personalis.
CNSDose has 3 investors. Key investors include Pitchblak, Melbourne Accelerator Program, and CNSDose.